Get started
Roivant Sciences Ltd.Roivant Sciences Ltd.Roivant Sciences Ltd.

Roivant Sciences Ltd.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast

A3C4MS chart


Full chart

A3C4MS upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪6.19 B‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.1326 EUR
Net income (FY)
‪4.03 B‬ EUR
Revenue (FY)
‪115.66 M‬ EUR
Shares float
‪438.67 M‬
Beta (1Y)
0.85

Employees


Employees (FY)
908
Change (1Y)
+4 +0.44%
Revenue / Employee (1Y)
‪127.38 K‬ EUR
Net income / Employee (1Y)
‪4.44 M‬ EUR

About Roivant Sciences Ltd.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Matthew Gline
Website
roivant.com
Headquarters
London
Founded
2021
FIGI
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

A3C4MS news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Check out other big names from the same industry as A3C4MS.

Frequently Asked Questions


The current price of A3C4MS is 8.6700 EUR — it has increased by 6.25% in the past 24 hours. Watch Roivant Sciences Ltd. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSX exchange Roivant Sciences Ltd. stocks are traded under the ticker A3C4MS.
A3C4MS stock has fallen by −0.25% compared to the previous week, the month change is a −11.37% fall, over the last year Roivant Sciences Ltd. has showed a −20.35% decrease.
We've gathered analysts' opinions on Roivant Sciences Ltd. future price: according to them, A3C4MS price has a max estimate of 20.10 EUR and a min estimate of 10.97 EUR. Watch A3C4MS chart and read a more detailed Roivant Sciences Ltd. stock forecast: see what analysts think of Roivant Sciences Ltd. and suggest that you do with its stocks.
A3C4MS reached its all-time high on Feb 10, 2025 with the price of 11.1200 EUR, and its all-time low was 8.1600 EUR and was reached on Apr 8, 2025. View more price dynamics on A3C4MS chart.
See other stocks reaching their highest and lowest prices.
A3C4MS stock is 6.34% volatile and has beta coefficient of 0.85. Track Roivant Sciences Ltd. stock price on the chart and check out the list of the most volatile stocks — is Roivant Sciences Ltd. there?
Today Roivant Sciences Ltd. has the market capitalization of ‪6.40 B‬, it has decreased by −7.00% over the last week.
Yes, you can track Roivant Sciences Ltd. financials in yearly and quarterly reports right on TradingView.
Roivant Sciences Ltd. is going to release the next earnings report on Jun 25, 2025. Keep track of upcoming events with our Earnings Calendar.
A3C4MS earnings for the last quarter are −0.20 EUR per share, whereas the estimation was −0.24 EUR resulting in a 19.65% surprise. The estimated earnings for the next quarter are −0.24 EUR per share. See more details about Roivant Sciences Ltd. earnings.
Roivant Sciences Ltd. revenue for the last quarter amounts to ‪8.71 M‬ EUR, despite the estimated figure of ‪4.83 M‬ EUR. In the next quarter, revenue is expected to reach ‪49.98 M‬ EUR.
A3C4MS net income for the last quarter is ‪163.62 M‬ EUR, while the quarter before that showed ‪−206.74 M‬ EUR of net income which accounts for 179.14% change. Track more Roivant Sciences Ltd. financial stats to get the full picture.
No, A3C4MS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 15, 2025, the company has 908 employees. See our rating of the largest employees — is Roivant Sciences Ltd. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Roivant Sciences Ltd. EBITDA is ‪−1.06 B‬ EUR, and current EBITDA margin is −847.72%. See more stats in Roivant Sciences Ltd. financial statements.
Like other stocks, A3C4MS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Roivant Sciences Ltd. stock right from TradingView charts — choose your broker and connect to your account.